Eyepoint’s Phase 3 program for Duravyu (vorolanib intravitreal insert) missed its primary goal, failing to show sustained vision maintenance with less frequent injections versus standard dosing. The negative readout threatens Eyepoint’s regulatory timeline after the Lugano trial fell short. The setback immediately reshaped the competitive wet AMD landscape: competing developer Ocular Therapeutix saw its shares rise on the implication that its later planned submission remains the clearer near-term path. Eyepoint is now expected to reconsider how it advances Duravyu toward approval. —